Eloxx Pharmaceuticals (NASDAQ:ELOX) Earns Buy Rating from Guggenheim

Eloxx Pharmaceuticals (NASDAQ:ELOX)‘s stock had its “buy” rating restated by research analysts at Guggenheim in a note issued to investors on Monday,Benzinga reports. They presently have a $43.00 target price on the stock. Guggenheim’s price objective would suggest a potential upside of 104.96% from the company’s previous close.

ELOX has been the topic of several other reports. Weiss Ratings assumed coverage on shares of Eloxx Pharmaceuticals in a research report on Friday, August 14th. They issued a “sell (d)” rating on the stock. Lucid Cap Mkts upgraded Eloxx Pharmaceuticals to a “strong-buy” rating in a research report on Thursday. Lifesci Capital started coverage on Eloxx Pharmaceuticals in a research note on Wednesday, July 22nd. They issued an “outperform” rating and a $40.00 target price on the stock. Finally, Wall Street Zen upgraded Eloxx Pharmaceuticals to a “hold” rating in a report on Saturday, August 1st. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $41.50.

Eloxx Pharmaceuticals Price Performance

Eloxx Pharmaceuticals stock opened at $20.98 on Monday. Eloxx Pharmaceuticals has a 52 week low of $8.20 and a 52 week high of $23.40. The stock has a 50-day simple moving average of $14.32. The stock has a market cap of $84.76 million, a price-to-earnings ratio of -13.62 and a beta of -1,863.11.

Eloxx Pharmaceuticals (NASDAQ:ELOX) last posted its earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.